Heteroresistance to fosfomycin is predominant in streptococcus pneumoniae and depends on the murA1 gene

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2801-2808

  Engel, Hansjürg ^a   Gutiérrez Fernández, Javier ^b   Flückiger, Christine ^a   Martínez Ripoll, Martín ^b   Mühlemann, Kathrin ^a,c   Hermoso, Juan A ^b   Hilty, Markus ^a,c   Hathaway, Lucy J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; FOSFOMYCIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE ENOLPYRUVYLTRANSFERASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CRYSTAL STRUCTURE; GENE DELETION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ALKYL AND ARYL TRANSFERASES; ANTI-BACTERIAL AGENTS; CRYSTALLIZATION; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; HUMANS; HUNGARY; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PNEUMOCOCCAL INFECTIONS; SEQUENCE ANALYSIS, DNA; STREPTOCOCCUS PNEUMONIAE;

EID: 84877857787     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00223-13     Document Type: Article

References (50)

1. Hakenbeck R, Grebe T, Zahner D, Stock JB. 1999.-Lactam resistance in Streptococcus pneumoniae: Penicillin-binding proteins and nonpenicillin-binding proteins. Mol. Microbiol. 33:673-678.
2. Contreras-Martel C, Dahout-Gonzalez C, Martins Ados S, Kotnik M, Dessen A. 2009. PBP active site flexibility as the key mechanism for β-lactam resistance in pneumococci. J. Mol. Biol. 387:899-909.
3. Zerfass I, Hakenbeck R, Denapaite D. 2009. An important site in PBP2x of penicillin-resistant clinical isolates of Streptococcus pneumoniae: Mutational analysis of Thr338. Antimicrob. Agents Chemother. 53:1107-1115.
4. Morand B, Mühlemann K. 2007. Heteroresistance to penicillin in Streptococcus pneumoniae. Proc. Natl. Acad. Sci. U. S. A. 104:14098-14103.
5. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. 2008. Heteroresistance: A concern of increasing clinical significance? Clin. Microbiol. Infect. 14:101-104.
6. Alam MR, Donabedian S, Brown W, Gordon J, Chow JW, Zervos MJ, Hershberger E. 2001. Heteroresistance to vancomycin in Enterococcus faecium. J. Clin. Microbiol. 39:3379-3381.
7. Hung KH, Wang MC, Huang AH, Yan JJ, Wu JJ. 2012. Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii. J. Clin. Microbiol. 50:721-726.
8. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950.
9. Rinder H, Mieskes KT, Loscher T. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:339-345.
10. de Lencastre H, Tomasz A. 1994. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2590-2598.
11. Ender M, Berger-Bächi B, McCallum N. 2009. A novel DNA-binding protein modulating methicillin resistance in Staphylococcus aureus. BMC Microbiol. 9:15. doi:10.1186/1471-2180-9-15.
12. Finan JE, Rosato AE, Dickinson TM, Ko D, Archer GL. 2002. Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression. Antimicrob. Agents Chemother. 46:24-30.
13. Hartman BJ, Tomasz A. 1986. Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 29:85-92.
14. Murakami K, Tomasz A. 1989. Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J. Bacteriol. 171:874-879.
15. Ryffel C, Strassle A, Kayser FH, Berger-Bächi B. 1994. Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38:724-728.
16. Tomasz A, Nachman S, Leaf H. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124-129.
17. Avery SV. 2006. Microbial cell individuality and the underlying sources of heterogeneity. Nat. Rev. Microbiol. 4:577-587.
18. Perales A, Martínez-Ripoll M, Fayos J, von Carstenn-Lichterfelde C, Fernandez M. 1982. The absolute configuration of active and inactive fosfomycin. Acta Crystallogr. B 38:2763-2764.
19. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 15:e732-e739.
20. Kikuchi K, Totsuka K, Shimizu K, Ishii T, Yoshida T, Orikasa Y. 1995. Effects of combination of benzylpenicillin and fosfomycin on penicillinresistant Streptococcus pneumoniae. Microb. Drug Resist. 1:185-189.
21. Miró JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A. 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillinsusceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 56:4511-4515.
22. Gunetileke KG, Anwar RA. 1968. Biosynthesis of uridine diphospho-Nacetylmuramic acid. II. Purification and properties of pyruvate-uridine diphospho-N-acetylglucosamine transferase and characterization of uridine diphospho-N-acetylenopyruvylglucosamine. J. Biol. Chem. 243: 5770-5778.
23. Walsh CT, Benson TE, Kim DH, Lees WJ. 1996. The versatility of phosphoenolpyruvate and its vinyl ether products in biosynthesis. Chem. Biol. 3:83-91.
24. Du W, Brown JR, Sylvester DR, Huang J, Chalker AF, So CY, Holmes DJ, Payne DJ, Wallis NG. 2000. Two active forms of UDP-Nacetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J. Bacteriol. 182:4146-4152.
25. Wanke C, Amrhein N. 1993. Evidence that the reaction of the UDP-Nacetylglucosamine 1-carboxyvinyltransferase proceeds through the Ophosphothioketal of pyruvic acid bound to Cys115 of the enzyme. Eur. J. Biochem. 218:861-870.
26. Marquardt JL, Brown ED, Lane WS, Haley TM, Ichikawa Y, Wong CH, Walsh CT. 1994. Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry 33:10646-10651.
27. Kim DH, Lees WJ, Walsh CT. 1995. Stereochemical analysis of the tetrahedral adduct formed at the active site of UDP-GlcNAc enolpyruvyl transferase from the pseudosubstrates, (E)-and (Z)-3-fluorophosphoenolpyruvate, in D2O. J. Am. Chem. Soc. 117:6380-6381.
28. Han H, Yang Y, Olesen SH, Becker A, Betzi S, Schonbrunn E. 2010. The fungal product terreic acid is a covalent inhibitor of the bacterial cell wall biosynthetic enzyme UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). Biochemistry 49:4276-4282.
29. Eschenburg S, Kabsch W, Healy ML, Schonbrunn E. 2003. A new view of the mechanisms of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) and 5-enolpyruvylshikimate-3-phosphate synthase (AroA) derived from X-ray structures of their tetrahedral reaction intermediate states. J. Biol. Chem. 278:49215-49222.
30. Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, Schonbrunn E. 2012. Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA). J. Biol. Chem. 287:12657-12667.
31. Schönbrunn E, Sack S, Eschenburg S, Perrakis A, Krekel F, Amrhein N, Mandelkow E. 1996. Crystal structure of UDP-N-acetylglucosamine enolpyruvyltransferase, the target of the antibiotic fosfomycin. Structure 4:1065-1075.
32. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 1996. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4:1465-1474.
33. Sung CK, Li H, Claverys JP, Morrison DA. 2001. An rpsL cassette, Janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl. Environ. Microbiol. 67:5190-5196.
34. Meier PS, Utz S, Aebi S, Mühlemann K. 2003. Low-level resistance to rifampin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:863-868.
35. Shevchuk NA, Bryksin AV, Nusinovich YA, Cabello FC, Sutherland M, Ladisch S. 2004. Construction of long DNA molecules using long PCRbased fusion of several fragments simultaneously. Nucleic Acids Res. 32: E19. doi:10.1093/nar/gnh014.
36. Brugger SD, Hathaway LJ, Mühlemann K. 2009. Detection of Streptococcus pneumoniae strain cocolonization in the nasopharynx. J. Clin. Microbiol. 47:1750-1756.
37. Hathaway LJ, Battig P, Mühlemann K. 2007. In vitro expression of the first capsule gene of Streptococcus pneumoniae, cpsA, is associated with serotype-specific colonization prevalence and invasiveness. Microbiology 153:2465-2471.
38. Matthews BW. 1968. Solvent content of protein crystals. J. Mol. Biol. 33:491-497.
39. Kabsch W. 2010. XDS. Acta Crystallogr. D Biol. Crystallogr. 66:125-132.
40. Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr. D. Biol. Crystallogr. 62:72-82.
41. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67:235-242.
42. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40: 658-674.
43. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davies IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: A comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
44. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
45. Chen VB, Arendall WB, III, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66:12-21.
46. Schönbrunn E, Eschenburg S, Krekel F, Luger K, Amrhein N. 2000. Role of the loop containing residue 115 in the induced-fit mechanism of the bacterial cell wall biosynthetic enzyme MurA. Biochemistry 39:2164-2173.
47. Meroueh SO, Roblin P, Golemi D, Maveyraud L, Vakulenko SB, Zhang Y, Samama JP, Mobashery S. 2002. Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM β-lactamase from Escherichia coli. J. Am. Chem. Soc. 124:9422-9430.
48. Hauser C, Aebi S, Mühlemann K. 2004. An internationally spread clone of Streptococcus pneumoniae evolves from low-level to higher-level penicillin resistance by uptake of penicillin-binding protein gene fragments from nonencapsulated pneumococci. Antimicrob. Agents Chemother. 48: 3563-3566.
49. Hathaway LJ, Stutzmann Meier P, Battig P, Aebi S, Mühlemann K. 2004. A homologue of aliB is found in the capsule region of nonencapsulated Streptococcus pneumoniae. J. Bacteriol. 186:3721-3729.
50. Bättig P, Mühlemann K. 2007. Capsule genes of Streptococcus pneumoniae influence growth in vitro. FEMS Immunol. Med. Microbiol. 50: 324-329.